Cost-efficacy ratios were derived as follows:
(1) average % decrease in symptom score/cost: the cost-efficacy ratio for a 1% decrease in patient-rated symptom score was $0.44 for fluticasone propionate and $0.86 for terfenadine.
(2) the number of patients at improvement standard 1/cost: $0.44 for fluticasone propionate and $0.86 for terfenadine.
(3) the number of patients at improvement standard 3/cost: $0.28 for fluticasone propionate and $0.49 for terfenadine.
Following the sensitivity analysis it was calculated that for every 30 days of fluticasone propionate treatment, between 11 and 18 days of efficacy-adjusted days of terfenadine could be purchased. If sensitivity analysis was not carried out, then the upper end of the range increased to 22 days.